Phase II clinical trials in oncology: Strengths and limitations of two-stage designs

James Schlesselman, Isildinha Reis

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Two-stage designs are used widely in Phase II oncology clinical trials to reduce the number of patients placed on ineffective experimental therapies. They provide clear-cut rules for stopping early in the event that treatment is not succeeding as hoped and are relatively simple to implement. Such designs, however, can lead to situations in which patient accrual is continued in the face of a clearly inferior treatment. In situations where patients' response can be determined for many or most subjects before additional patients are enrolled, analyses using Bayesian methodology can lead to earlier termination of studies of ineffective treatments and better align the statistical assessment of treatment effect with the therapeutic objectives of study. These points are discussed in context of the role of Phase II clinical trials in the development of new treatments for cancer.

Original languageEnglish
Pages (from-to)404-412
Number of pages9
JournalCancer Investigation
Volume24
Issue number4
DOIs
StatePublished - Jun 1 2006

Fingerprint

Phase II Clinical Trials
Therapeutics
Investigational Therapies
Bayes Theorem
Therapeutic Uses
Neoplasms

Keywords

  • Bayesian methods
  • Clinical trials
  • Phase II studies
  • Two-stage designs

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase II clinical trials in oncology : Strengths and limitations of two-stage designs. / Schlesselman, James; Reis, Isildinha.

In: Cancer Investigation, Vol. 24, No. 4, 01.06.2006, p. 404-412.

Research output: Contribution to journalArticle

@article{18e692b2012b49a593fa59aa8ce410aa,
title = "Phase II clinical trials in oncology: Strengths and limitations of two-stage designs",
abstract = "Two-stage designs are used widely in Phase II oncology clinical trials to reduce the number of patients placed on ineffective experimental therapies. They provide clear-cut rules for stopping early in the event that treatment is not succeeding as hoped and are relatively simple to implement. Such designs, however, can lead to situations in which patient accrual is continued in the face of a clearly inferior treatment. In situations where patients' response can be determined for many or most subjects before additional patients are enrolled, analyses using Bayesian methodology can lead to earlier termination of studies of ineffective treatments and better align the statistical assessment of treatment effect with the therapeutic objectives of study. These points are discussed in context of the role of Phase II clinical trials in the development of new treatments for cancer.",
keywords = "Bayesian methods, Clinical trials, Phase II studies, Two-stage designs",
author = "James Schlesselman and Isildinha Reis",
year = "2006",
month = "6",
day = "1",
doi = "10.1080/07357900600705516",
language = "English",
volume = "24",
pages = "404--412",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Phase II clinical trials in oncology

T2 - Strengths and limitations of two-stage designs

AU - Schlesselman, James

AU - Reis, Isildinha

PY - 2006/6/1

Y1 - 2006/6/1

N2 - Two-stage designs are used widely in Phase II oncology clinical trials to reduce the number of patients placed on ineffective experimental therapies. They provide clear-cut rules for stopping early in the event that treatment is not succeeding as hoped and are relatively simple to implement. Such designs, however, can lead to situations in which patient accrual is continued in the face of a clearly inferior treatment. In situations where patients' response can be determined for many or most subjects before additional patients are enrolled, analyses using Bayesian methodology can lead to earlier termination of studies of ineffective treatments and better align the statistical assessment of treatment effect with the therapeutic objectives of study. These points are discussed in context of the role of Phase II clinical trials in the development of new treatments for cancer.

AB - Two-stage designs are used widely in Phase II oncology clinical trials to reduce the number of patients placed on ineffective experimental therapies. They provide clear-cut rules for stopping early in the event that treatment is not succeeding as hoped and are relatively simple to implement. Such designs, however, can lead to situations in which patient accrual is continued in the face of a clearly inferior treatment. In situations where patients' response can be determined for many or most subjects before additional patients are enrolled, analyses using Bayesian methodology can lead to earlier termination of studies of ineffective treatments and better align the statistical assessment of treatment effect with the therapeutic objectives of study. These points are discussed in context of the role of Phase II clinical trials in the development of new treatments for cancer.

KW - Bayesian methods

KW - Clinical trials

KW - Phase II studies

KW - Two-stage designs

UR - http://www.scopus.com/inward/record.url?scp=33745296061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745296061&partnerID=8YFLogxK

U2 - 10.1080/07357900600705516

DO - 10.1080/07357900600705516

M3 - Article

C2 - 16777694

AN - SCOPUS:33745296061

VL - 24

SP - 404

EP - 412

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 4

ER -